SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported)
(Exact Name of Registrant as Specified in its Charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class: |
Trading Symbol(s) |
Name of each exchange on which registered: | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company indicate by check mark if the registrant has elected not to use the extended transaction period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On March 4, 2021, J. Michael Bruff notified Varian Medical Systems, Inc. (the “Company”) that he would be resigning as Chief Financial Officer of the Company, effective March 12, 2021, to pursue other opportunities.
Magnus Momsen, Senior Vice President, Chief Accounting Officer and Corporate Controller, will serve as the Company’s interim Chief Financial Officer effective March 12, 2021. Mr. Momsen, age 46, has significant leadership experience at the Company, having served as the Company’s Senior Vice President, Chief Accounting Officer and Corporate Controller and the Company’s Principal Accounting Officer since January 2017. Mr. Momsen joined the Company in September 2010 as Controller, Emerging Businesses, where he was responsible for the financial oversight of the Particle Therapy and Security and Inspection products businesses, and from August 2012 to January 2017, Mr. Momsen served as the Company’s Vice President and Assistant Corporate Controller, responsible for the SEC reporting, technical accounting and Corporate accounting departments.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: March 8, 2021
| VARIAN MEDICAL SYSTEMS, INC. | ||
| By: | /s/ Michael D. Hutchinson | |
| Name: | Michael D. Hutchinson | |
| Title: | SVP, Chief Legal Officer, Corporate Secretary | |